SCHEMBL4908473

SCHEMBL4908473

COc1cc(Br)ccc1B(O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.52
TDP1 Q9NUW8 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ERN1 O75460 1/20 0.42
TUBB4A P04350 4/20 0.41
TUBB P07437 4/20 0.41
TUBA3C P0DPH7 4/20 0.41
TUBA1B P68363 4/20 0.41
TUBA4A P68366 4/20 0.41
TUBB4B P68371 4/20 0.41
TUBB3 Q13509 4/20 0.41
TUBB2A Q13885 4/20 0.41
TUBB8 Q3ZCM7 4/20 0.41
TUBA3E Q6PEY2 4/20 0.41
TUBA1A Q71U36 4/20 0.41
TUBA1C Q9BQE3 4/20 0.41
TUBB6 Q9BUF5 4/20 0.41
TUBB2B Q9BVA1 4/20 0.41
TUBB1 Q9H4B7 4/20 0.41
ORAI1 Q96D31 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30214822 1.00 ENPP2 (0.52) ENPP2TDP1KDM4EERN1TUBB4A
SCHEMBL1235272 0.83 ENPP2 (0.52) ENPP2TDP1KDM4ETUBB4ATUBB
SCHEMBL12004570 0.77 MAOA (0.40) ENPP2TDP1MEN1LMNAMAPT
SCHEMBL15019984 0.77 CFD (0.46) TDP1KDM4EMEN1LMNAMAPT
SCHEMBL30214860 0.77 MAOA (0.40) ENPP2TDP1MEN1LMNAMAPT
SCHEMBL25173988 0.77 ENPP2 (0.54) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL203357 0.77 CA1 (0.58) ENPP2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1228414 0.77 ACHE (0.58) ENPP2ERN1TUBB4ATUBBTUBA3C
SCHEMBL29955197 0.77 ACHE (0.58) ENPP2ERN1TUBB4ATUBBTUBA3C
SCHEMBL29496939 0.77 CA1 (0.58) ENPP2TUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113896680-B PH response type supermolecule nanotube monomer molecule and preparation method and application thereof 中山大学 2023-06-30 CN claimed
US-12622132-B2 Light-emitting device, light-emitting apparatus, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2026-05-05 US disclosed
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS KOJIN THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4565228-A2 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS Kojin Therapeutics, Inc. (US) 2025-06-11 EP disclosed
CN-119684814-A Yellow dichromatic dye and application thereof 烟台海森大数据有限公司 2025-03-25 CN disclosed
CN-119462581-A Preparation method of 3-bromo-7-chlorodibenzo [ b, d ] furan 中钢天源股份有限公司 2025-02-18 CN disclosed
US-20250042879-A1 HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME RGENTA THERAPEUTICS, INC. 2025-02-06 US disclosed
CN-118843625-A Heterocyclically substituted 1,3, 4-thiadiazole and pyridazine compounds and methods of use thereof 亚根达医疗公司 2024-10-25 CN disclosed
EP-4436665-A1 HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME Rgenta Therapeutics, Inc. (US) 2024-10-02 EP disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 US disclosed
US-20150133512-A1 N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS HOFFMANN-LA ROCHE INC. 2015-05-14 US disclosed
EP-2864301-A1 N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2015-04-29 EP disclosed
US-8951993-B2 Phosphorus containing compounds as protein kinase inhibitors JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) 2015-02-10 US disclosed
WO-2014121055-A2 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-08-07 WO disclosed
US-20140221311-A1 FLAP MODULATORS JANSSEN PHARMACEUTICA NV (US) 2014-08-07 US disclosed
WO-2013189865-A1 N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2013-12-27 WO disclosed
WO-2012116050-A2 PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS Eternity Bioscience Inc. (US) 2012-08-30 WO disclosed
US-20120220551-A1 PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS Eternity Bioscience Inc. (US) 2012-08-30 US disclosed
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2008-01-17 US disclosed
WO-2006060762-A2 PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12622132-B2 Light-emitting device, light-emitting apparatus, electronic device, and lighting device CYBA, NFE2L2, AOX1 ENPP2 4433/4885TDP1 2061/4885KDM4E 1022/4885
US-20080015223-A1 Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto HTR5A, HTR2A, HTR3A ENPP2 487/4885TDP1 2235/4885KDM4E 3183/4885
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 ENPP2 420/4885TDP1 2502/4885KDM4E 2198/4885
US-20120220551-A1 PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS PPM1A, PPM1G, PPM1B ENPP2 312/4885TDP1 1520/4885KDM4E 1177/4885
US-20150133512-A1 N-ARYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS LPAR1, LPAR2, LPAR3 ENPP2 24/4885TDP1 4290/4885KDM4E 3915/4885
US-20260034094-A1 COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS AIFM2, GPX4, HMOX1 ENPP2 977/4885TDP1 4871/4885KDM4E 2580/4885
US-20250042879-A1 HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME RBM17, SF3B5, SF3A2 ENPP2 1800/4885TDP1 178/4885KDM4E 3107/4885
US-20140221311-A1 FLAP MODULATORS PGF, FEN1, TBXA2R ENPP2 1508/4885TDP1 646/4885KDM4E 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.